Terms: = Liver cancer AND HSP90AA1, ENSG00000080824, 3320, P07900, LAP2, HSPN, HSPCAL4, HSPCAL1, HSPCA, HSPC1, HSP90N, HSP90A, Hsp90, Hsp89, HSP86, FLJ31884 AND Diagnosis
11 results:
1. An HBV susceptibility variant of KNG1 modulates the therapeutic effects of interferons α and λ1 in HBV infection by promoting MAVS lysosomal degradation.
Zhang B; Han H; Zhao X; Li AN; Wang Y; Yuan W; Yang Z; Li MD
EBioMedicine; 2023 Aug; 94():104694. PubMed ID: 37442062
[TBL] [Abstract] [Full Text] [Related]
2. Impact of hsp90
Zhou W; Yang Y; Wang Z; Liu Y; Lari Najafi M
J Healthc Eng; 2021; 2021():6929971. PubMed ID: 34721827
[TBL] [Abstract] [Full Text] [Related]
3. Intrahepatic Cholangiocarcinoma: State of the Art of FGFR Inhibitors.
Wu T; Jiang X; Zhang X; Wu B; Xu B; Liu X; Zheng L; Wang Y
Cancer Control; 2021; 28():1073274821989314. PubMed ID: 33618536
[TBL] [Abstract] [Full Text] [Related]
4. Diagnostic value of plasma hsp90α levels for detection of hepatocellular carcinoma.
Wei W; Liu M; Ning S; Wei J; Zhong J; Li J; Cai Z; Zhang L
BMC Cancer; 2020 Jan; 20(1):6. PubMed ID: 31898536
[TBL] [Abstract] [Full Text] [Related]
5. Overexpression of heat shock protein hsp90aa1 and translocase of the outer mitochondrial membrane TOM34 in HCV-induced hepatocellular carcinoma: A pilot study.
Toraih EA; Alrefai HG; Hussein MH; Helal GM; Khashana MS; Fawzy MS
Clin Biochem; 2019 Jan; 63():10-17. PubMed ID: 30521791
[TBL] [Abstract] [Full Text] [Related]
6. Identification and Therapeutic Intervention of Coactivated Anaplastic Lymphoma Kinase, Fibroblast Growth Factor Receptor 2, and Ephrin Type-A Receptor 5 Kinases in Hepatocellular Carcinoma.
Wang X; Zhang M; Ping F; Liu H; Sun J; Wang Y; Shen A; Ding J; Geng M
Hepatology; 2019 Feb; 69(2):573-586. PubMed ID: 29356025
[TBL] [Abstract] [Full Text] [Related]
7. [Stable isotope labeling and parallel reaction monitoring-based proteomic quantification for biomarker screening and validation of hepatocellular carcinoma].
Wang S; Gao H; Zhang J; Ye X
Se Pu; 2017 Sep; 35(9):934-940. PubMed ID: 29048850
[TBL] [Abstract] [Full Text] [Related]
8. Transcriptomic and Proteomic Investigation of hsp90a as a Potential Biomarker for HCC.
Zhou Y; Deng X; Zang N; Li H; Li G; Li C; He M
Med Sci Monit; 2015 Dec; 21():4039-49. PubMed ID: 26704341
[TBL] [Abstract] [Full Text] [Related]
9. Organ-specific efficacy of hsp90 inhibitor in multiple-organ metastasis model of chemorefractory small cell lung cancer.
Takeuchi S; Fukuda K; Arai S; Nanjo S; Kita K; Yamada T; Hara E; Nishihara H; Uehara H; Yano S
Int J Cancer; 2016 Mar; 138(5):1281-9. PubMed ID: 26379118
[TBL] [Abstract] [Full Text] [Related]
10. Differential proteomics identification of hsp90 as potential serum biomarker in hepatocellular carcinoma by two-dimensional electrophoresis and mass spectrometry.
Sun Y; Zang Z; Xu X; Zhang Z; Zhong L; Zan W; Zhao Y; Sun L
Int J Mol Sci; 2010 Mar; 11(4):1423-33. PubMed ID: 20480028
[TBL] [Abstract] [Full Text] [Related]
11. Gastric cancer and metastasis to the brain.
York JE; Stringer J; Ajani JA; Wildrick DM; Gokaslan ZL
Ann Surg Oncol; 1999 Dec; 6(8):771-6. PubMed ID: 10622506
[TBL] [Abstract] [Full Text] [Related]
